Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Summary

The purpose of this phase I/II study is to evaluate the progression free survival at 8 weeks (PFS8week) of the combination of LEE011 plus everolimus in patients with metastatic pancreatic cancer refractory to 5-fluorouracil (5-FU) and gemcitabine-based chemotherapy.

General Information

NCT#: NCT02985125
Study ID: 2016-0232
Trial Phase: Phase I/II

Trial Sponsor: Georgetown University
Therapies Used in This Trial: Everolimus, Ribociclib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search